The BioNJ Diagnostics and Precision Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, the government and investors in the State of New Jersey.
The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.
Peter Hoehn, Committee Co-Chair, Global Business Leader, Janssen Diagnostics
Peter Tolias, Ph.D., Committee Co-Chair, Professor and Director, Center for Healthcare Innovation, Stevens Institute
Howard Bell, CEO, Intelligent Material Solutions, Inc.
Andrew Brooks, Ph.D., Chief Operating Office, RUCDR, Infinite Biologics
Ger Brophy, B.Sc., Ph.D., General Manager, GE Healthcare Peter Hoehn, Global Business Leader, Janssen Diagnostics
Jan De Backer, MSc, Ph.D., MBA, Chief Executive Officer, FluidDA, Inc.
Guanghui Hu, President, Admera Health
Courtney Kronenthal, PhD., Director, Communications and Development, Coriell Institute for Medical Research
Nancy Lurker, Chief Executive Officer, PDI, Inc.
Joe Montemarano, MIRTHE Executive Director, Princeton University
Christopher Moxham, Ph.D., Associate Vice President, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Co.
Roomi Nusrat, M.D., Consultant, Aesclepius Sciences, LLC
Lieven Nuyttens, Chief Executive Officer, U.S. Division, FluidDA, Inc.
Kapila Ratnam, Principal, NewSpring Capital
Panna Sharma, President & CEO, Cancer Genetics, Inc.
Jacqueline Threadgill, Consultant, Senergene Solutions
Pascal Yvon, PharmD, MBA, President, BioSciences Expansion
Members of the BioNJ Diagnostics and Personalized Medicine Committee
join May 2011 Webinar Panelists at BioNJ Headquarters.
If you are interested in becoming a sponsor of the BioNJ Diagnostics and Personalized Medicine
Committee, please contact BioNJ at BioNJ@BioNJ.org or by phone at 609-890-3185.